Adrenal steroidogenesis disruption caused by HDL/cholesterol suppression in diethylstilbestrol-treated adult male rat

Endocrine
Satoko HaenoHiroshi Yokota

Abstract

The synthetic estrogen diethylstilbestrol is used to prevent miscarriages and as a therapeutic treatment for prostate cancer, but it has been reported to have adverse effects on endocrine homeostasis. However, the toxicity mechanism is poorly understood. Recently, we reported that diethylstilbestrol impairs adrenal steroidogenesis via cholesterol insufficiency in adult male rats. In the present study, we found that the adrenal cholesterol level was significantly reduced without of the decrease in other precursors in the adrenal steroidogenesis 24 h after a single dose of diethylstilbestrol (0.33 μg/g body mass). The serum HDL/cholesterol level was also reduced only 12 h after the diethylstilbestrol exposure. The level of Apo E, which is indispensable for HDL/cholesterol maturation, was decreased in both the HDL and VLDL/LDL fractions, whereas the level of Apo A1, which is an essential constituent of HDL, was not altered in the HDL fraction. Because the liver is a major source of Apo E and Apo A1, the secretion rates of these proteins were examined using a liver perfusion experiment. The secretion rate of Apo A1 from the liver was consistent between DES-treated and control rats, but that of Apo E was comparatively suppressed in ...Continue Reading

References

Nov 9, 1989·The New England Journal of Medicine·D J Gordon, B M Rifkind
Jan 1, 1985·Archives of Toxicology. Supplement. = Archiv Für Toxikologie. Supplement·K S Korach, J A McLachlan
May 15, 1995·Annals of Internal Medicine·R M GiustiE E Hatch
Jun 18, 2003·Endocrinology·Susanne K DrosteJohannes M H M Reul
Mar 15, 2006·Nature Neuroscience·Alexis M StranahanElizabeth Gould
Jan 9, 2007·The Biochemical Journal·Kyriakos E Kypreos, Vassilis I Zannis
Jan 9, 2007·Molecular and Cellular Endocrinology·Fredric B Kraemer
Jan 9, 2008·Steroids·Chandrakesan Parthasarathy, Karundevi Balasubramanian
Feb 22, 2008·Environmental Health Perspectives·Olwenn V MartinNikolaos Voulvoulis
Mar 13, 2008·Journal of Cellular Biochemistry·C Parthasarathy, K Balasubramanian
Oct 9, 2008·Molecular and Cellular Endocrinology·Margery A Connelly
May 16, 2009·The Journal of Reproduction and Development·Jae-Ho ShinSoon-Young Han
Jun 9, 2009·Endocrine Reviews·Evanthia Diamanti-KandarakisAndrea C Gore
Aug 20, 2009·Environmental Health : a Global Access Science Source·Julie R PalmerRobert N Hoover
Feb 2, 2011·Experimental Neurology·Timothy J Schoenfeld, Elizabeth Gould
Apr 27, 2012·Journal of Nutrition and Metabolism·Jovana Kaludjerovic, Wendy E Ward
Jun 8, 2012·Journal of Clinical Research in Pediatric Endocrinology·Tolga Unüvar, Atilla Büyükgebiz
Oct 12, 2012·Journal of Biochemistry·Naoyuki MaedaHiroshi Yokota
Mar 1, 2014·The Journal of Endocrinology·Satoko HaenoHiroshi Yokota
May 13, 2014·The Journal of Steroid Biochemistry and Molecular Biology·Richard HamplLuboslav Stárka

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.